This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (33) Citing Articles via Google Scholar Google Scholar Articles by Zarate, E. Articles by Stewart, D. G. Search for Related Content PubMed PubMed Citation Articles by Zarate, E. Articles by Stewart, D. G.

---

AMBULATORY ANESTHESIA

A Comparison of the Costs and Efficacy of Ondansetron Versus Dolasetron for Antiemetic Prophylaxis

Eduardo Zarate, MD^*, Mehernoor F. Watcha, MD, Paul F. White, PhD, MD, FANZCA^*, Kevin W. Klein, MD^*, Monica Sa Rego, MD^*, and D. Greg Stewart, MS^*

*Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas; and Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Address correspondence to Paul F. White, PhD, MD, FANZCA, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, 5161 Harry Hines Blvd., CS2.126, Dallas, TX 75235-9068. Address e-mail to pwhite{at}mednet.swmed.edu

The optimal dose and timing of 5-HT₃ antagonist administration for prophylaxis against postoperative nausea and vomiting (PONV) remains controversial. Although 5-HT₃ antagonists seem to be most effective when administered near the end of surgery, there are no data on the comparative efficacy or costs associated with the 5-HT₃ antagonists dolasetron and ondansetron when administered at the end of the operation. In this double-blinded study, 200 outpatients undergoing otolaryngologic procedures with a standardized general anesthetic received 4 (O4) or 8 mg (O8) of ondansetron or 12.5 (D12.5) or 25 mg (D25) of dolasetron IV within 30 min before the end of surgery. A blinded observer recorded the emetic episodes, maximum nausea score, recovery room resource and drug use, nursing time spent managing PONV, times to achieve discharge criteria from the Phase 1 and 2 recovery units, postdischarge emesis, and patient satisfaction. Total costs were calculated by using the perspective of a free-standing surgicenter. There were no differences in patient demographics, incidence of PONV, need for rescue medications, time spent in the recovery areas, unanticipated hospital admissions, or patient satisfaction among the four treatment groups. The mean total costs (95% confidence intervals) to prevent PONV in one patient were lowest in the D12.5 group: $23.89 (17.18–28.79) vs $37.81 (30.29–45.32), $33.91 (28.92–39.35), and $75.18 (61.13–89.24) for D25, O4, and O8, respectively. Excluding nursing labor costs did not alter this finding: $18.51 (14.18–22.85), $34.77 (28.03–41.49), $31.77 (28.92–39.35), and $71.76 (58.17–85.35) for D12.5, D25, O4, and O8, respectively. We conclude that 12.5 mg of dolasetron IV is more cost effective than 4 mg of ondansetron IV for preventing PONV after otolaryngologic surgery and is associated with similar patient satisfaction.

Implications: When administered at the end of surgery, 12.5 mg of dolasetron IV is as effective as 25 mg of dolasetron IV, 4 mg of ondansetron IV, and 8 mg of ondansetron IV in preventing emetic symptoms after otolaryngologic surgery and was associated with similar patient satisfaction at a reduced cost. There were no differences in the antiemetic efficacy of the 4 and 8 mg doses of ondansetron.

This article has been cited by other articles:

				S. M Wilhelm, M. L Dehoorne-Smith, and P. B Kale-Pradhan Prevention of Postoperative Nausea and Vomiting Ann. Pharmacother., January 1, 2007; 41(1): 68 - 78. [Abstract] [Full Text] [PDF]

				J. M. Richman, S. S. Liu, G. Courpas, R. Wong, A. J. Rowlingson, J. McGready, S. R. Cohen, and C. L. Wu Does Continuous Peripheral Nerve Block Provide Superior Pain Control to Opioids? A Meta-Analysis Anesth. Analg., January 1, 2006; 102(1): 248 - 257. [Abstract] [Full Text] [PDF]

				P. F. White Treatment of Postoperative Nausea and Vomiting with Dolasetron Versus Ondansetron: Is There a Conflict of Interest? Anesth. Analg., December 1, 2005; 101(6): 1887 - 1887. [Full Text] [PDF]

				J. Golembiewski, E. Chernin, and T. Chopra Prevention and treatment of postoperative nausea and vomiting Am. J. Health Syst. Pharm., June 15, 2005; 62(12): 1247 - 1260. [Abstract] [Full Text] [PDF]

				T. A. Meyer, C. R. Roberson, M. H. Rajab, J. Davis, and C. H. McLeskey Dolasetron Versus Ondansetron for the Treatment of Postoperative Nausea and Vomiting Anesth. Analg., February 1, 2005; 100(2): 373 - 377. [Abstract] [Full Text] [PDF]

				O. Olutoye, E. C. Jantzen, R. Alexis, D. Rajchert, M. S. Schreiner, and M. F. Watcha A Comparison of the Costs and Efficacy of Ondansetron and Dolasetron in the Prophylaxis of Postoperative Vomiting in Pediatric Patients Undergoing Ambulatory Surgery Anesth. Analg., August 1, 2003; 97(2): 390 - 396. [Abstract] [Full Text] [PDF]

				A. Recart, T. Issioui, P. F. White, K. Klein, M. F. Watcha, L. Stool, and M. Shah The Efficacy of Celecoxib Premedication on Postoperative Pain and Recovery Times After Ambulatory Surgery: A Dose-Ranging Study Anesth. Analg., June 1, 2003; 96(6): 1631 - 1635. [Abstract] [Full Text] [PDF]

				K. Garrett, K. Tsuruta, S. Walker, S. Jackson, and M. Sweat Managing Nausea and Vomiting: Current Strategies Crit. Care Nurse, February 1, 2003; 23(1): 31 - 50. [Full Text] [PDF]

				M. A. Burmeister, T. G. Standl, M. Wintruff, P. Brauer, I. Blanc, and J. Schulte am Esch Dolasetron prophylaxis reduces nausea and postanaesthesia recovery time after remifentanil infusion during monitored anaesthesia care for extracorporeal shock wave lithotripsy Br. J. Anaesth., February 1, 2003; 90(2): 194 - 198. [Abstract] [Full Text] [PDF]

				M. J. Sanchez-Ledesma, L. Lopez-Olaondo, F. J. Pueyo, F. Carrascosa, and A. Ortega A Comparison of Three Antiemetic Combinations for the Prevention of Postoperative Nausea and Vomiting Anesth. Analg., December 1, 2002; 95(6): 1590 - 1595. [Abstract] [Full Text] [PDF]

				T. Issioui, K. W. Klein, P. F. White, M. F. Watcha, M. Coloma, G. D. Skrivanek, S. B. Jones, K. C. Thornton, and B. F. Marple The Efficacy of Premedication with Celecoxib and Acetaminophen in Preventing Pain After Otolaryngologic Surgery Anesth. Analg., May 1, 2002; 94(5): 1188 - 1193. [Abstract] [Full Text] [PDF]

				T. J. Gan Postoperative Nausea and Vomiting--Can It Be Eliminated? JAMA, March 13, 2002; 287(10): 1233 - 1236. [Full Text] [PDF]

				X. Chen, J. Tang, P. F. White, R. H. Wender, R. Quon, A. Sloninsky, R. Naruse, R. Kariger, T. Webb, and E. Norel The Effect of Timing of Dolasetron Administration on its Efficacy as a Prophylactic Antiemetic in the Ambulatory Setting Anesth. Analg., October 1, 2001; 93(4): 906 - 911. [Abstract] [Full Text] [PDF]

				H. R. Munoz, J. A. Dagnino, and B. Larsen Power Analysis with More than Two Groups Anesth. Analg., March 1, 2001; 92(3): 797 - 797. [Full Text] [PDF]